Bank of America
GTBP icon

Bank of America’s GT Biopharma GTBP Stock Holding History

Bank of America’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24
Closed -$19 – 6207
2025
Q4 		$19 Hold
24
– – ﹤0.01% 7131
2025
Q3 		$14 Sell
24
-5
-17% -$7 ﹤0.01% 8198
2025
Q2 		$104 Buy
29
+2
+7% +$5 ﹤0.01% 7962
2025
Q1 		$59 Hold
27
– – ﹤0.01% 7942
2024
Q4 		$82 Hold
27
– – ﹤0.01% 7782
2024
Q3 		$62 Hold
27
– – ﹤0.01% 7800
2024
Q2 		$76 Buy
27
+10
+59% +$36 ﹤0.01% 7765
2024
Q1 		$75 Sell
17
-19
-53% -$100 ﹤0.01% 7422
2023
Q4 		$273 Buy
36
+19
+112% +$139 ﹤0.01% 7336
2023
Q3 		$122 Buy
+17
New +$141 ﹤0.01% 7459
2023
Q2 		– Sell
-1
Closed -$10 – 7798
2023
Q1 		$18 Sell
1
-1
-50% -$23 ﹤0.01% 7578
2022
Q4 		$64 Buy
+2
New +$100 ﹤0.01% 7758
2022
Q3 		– Sell
-1,376
Closed -$124K – 7992
2022
Q2 		$124K Sell
1,376
-274
-17% -$20.8K ﹤0.01% 6370
2022
Q1 		$142K Sell
1,650
-1,316
-44% -$116K ﹤0.01% 6670
2021
Q4 		$272K Buy
2,966
+84
+3% +$12.6K ﹤0.01% 6316
2021
Q3 		$583K Buy
2,882
+2,613
+971% +$786K ﹤0.01% 5532
2021
Q2 		$125K Buy
+269
New +$112K ﹤0.01% 6390

Other funds holding GTBP

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return

Bank of America's GTBP Position: Q1 2026 in Review

Bank of America sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 24 shares — an estimated $19 sold.

Bank of America first reported a position in GTBP in Q2 2021 and held it in 17 quarters. The position peaked at $583K in Q3 2021. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Bank of America reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 24 GT Biopharma shares in Q1 2026, an estimated $19.
  • Bank of America first reported a position in GT Biopharma in Q2 2021 and held it in 17 quarters.
  • Bank of America's GT Biopharma position peaked at $583K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.